HomeCompareJRJC vs ABBV

JRJC vs ABBV: Dividend Comparison 2026

JRJC yields 50.13% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JRJC wins by $294.2K in total portfolio value
10 years
JRJC
JRJC
● Live price
50.13%
Share price
$3.99
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$396.6K
Annual income
$80,528.40
Full JRJC calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — JRJC vs ABBV

📍 JRJC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJRJCABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JRJC + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JRJC pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JRJC
Annual income on $10K today (after 15% tax)
$4,260.65/yr
After 10yr DRIP, annual income (after tax)
$68,449.14/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, JRJC beats the other by $47,393.14/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JRJC + ABBV for your $10,000?

JRJC: 50%ABBV: 50%
100% ABBV50/50100% JRJC
Portfolio after 10yr
$249.4K
Annual income
$52,650.08/yr
Blended yield
21.11%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

JRJC
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JRJC buys
0
ABBV buys
0
No recent congressional trades found for JRJC or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJRJCABBV
Forward yield50.13%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$396.6K$102.3K
Annual income after 10y$80,528.40$24,771.77
Total dividends collected$316.6K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: JRJC vs ABBV ($10,000, DRIP)

YearJRJC PortfolioJRJC Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$15,713$5,012.53$11,550$430.00+$4.2KJRJC
2$24,173$7,360.71$13,472$627.96+$10.7KJRJC
3$36,449$10,583.33$15,906$926.08+$20.5KJRJC
4$53,914$14,913.72$19,071$1,382.55+$34.8KJRJC
5$78,304$20,616.79$23,302$2,095.81+$55.0KJRJC
6$111,771$27,984.95$29,150$3,237.93+$82.6KJRJC
7$156,927$37,332.09$37,536$5,121.41+$119.4KJRJC
8$216,897$48,985.50$50,079$8,338.38+$166.8KJRJC
9$295,356$63,276.23$69,753$14,065.80+$225.6KJRJC
10$396,559$80,528.40$102,337$24,771.77+$294.2KJRJC

JRJC vs ABBV: Complete Analysis 2026

JRJCStock

China Finance Online Co. Limited, together with its subsidiaries, provides web-based financial services in the People's Republic of China and Hong Kong. The company operates through two segments: Hong Kong Brokerage Services and Financial Services. It provides online access to securities trading services, wealth management products, and securities investment advisory services to retail investors; and financial database and analytics to institutional investors, including financial, research, academic, and regulatory institutions, as well as financial software products. The company is also involved in the operation of Yinglibao, an internet-based financial platform that integrates cash management solutions and mutual fund distribution into iTougu, which facilitates communication between securities investment advisors and their clients; JRJ mobile app for financial information, securities trading, investment advisory, and wealth management; jrj.com.cn to provide access for wealth management solutions and mutual fund distribution; jrj.com, a financial information website; and iTAMP, a turnkey asset management platform that offers investment consultations and advice covering stocks, mutual funds, wealth management, insurance, trusts, and other financial products. In addition, it provides securities and futures contracts brokerage and related services to its customers, who invest in stocks listed on The Stock Exchange of Hong Kong Limited; subscription to financial analysis tools, real-time and historical data, news, research reports, and online forums; asset management and insurance brokerage services; and advertising and enterprise value-added services, as well as online P2P lending and money lending services. China Finance Online Co. Limited has a strategic partnership agreement with Citic Securities to provide internet financial services. The company was incorporated in 1998 and is based in Beijing, the People's Republic of China.

Full JRJC Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this JRJC vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JRJC vs SCHDJRJC vs JEPIJRJC vs OJRJC vs KOJRJC vs MAINJRJC vs JNJJRJC vs MRKJRJC vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.